Overall We will establish an Alzheimer's Disease Research Center (ADRC) at Stanford University to serve as a shared resource to facilitate and enhance multidisciplinary and interdisciplinary research in Alzheimer's disease and related disorders. Our mission is to specialize in the collection, analysis and dissemination of data sets that are relevant to two common neurodegenerative illnesses, Alzheimer's disease and Parkinson's disease. The new Stanford ADRC will emphasize particular strengths in neuroimmunity and synapse biology, as well as strengths in imaging, clinical assessment and clinical research, biostatistics, and caregiver outreach. Outreach activities will focus specificaly on underserved urban Hispanic/Latino and American Indian communities. To accomplish these goals, we will establish core resources for human studies; make available biospecimens and biomarker data; provide structural and functional neuroimaging; maintain an administrative structure and consultative resources appropriate for these goals; provide community-based outreach and educational programs and research participation opportunities; support Center-sponsored research projects and pilot projects on these disorders; and support national efforts to understand disease mechanisms and find effective forms of therapy and prevention.
We will establish an Alzheimer's Disease Research Center (ADRC) at Stanford University for new research collaborations that advance knowledge about, and aid in the prevention and treatment of Alzheimer's disease, Parkinson's disease, and related disorders. The Stanford ADRC will study healthy older adults and patients at early stages of their illness, followed over time. We are particularly interested in how the immune system affects the process of these disorders and the relation between changes in nerve synapses and disease progression.
|Harvey, Zachary H; Chen, Yiwen; Jarosz, Daniel F (2018) Protein-Based Inheritance: Epigenetics beyond the Chromosome. Mol Cell 69:195-202|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Clark, Jennie Leeder; Phoenix, Sarah; Bilbrey, Ann Choryan et al. (2018) Cultural Competency in Dementia Care: An African American Case Study. Clin Gerontol 41:255-260|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
|Turk, Katherine W; Flanagan, Margaret E; Josephson, Samuel et al. (2018) Psychosis in Spinocerebellar Ataxias: a Case Series and Study of Tyrosine Hydroxylase in Substantia Nigra. Cerebellum 17:143-151|
|Bharadwaj, Rajnish; Cimino, Patrick J; Flanagan, Margaret E et al. (2018) Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. Histopathology 72:433-440|
|Flanagan, Margaret E; Cholerton, Brenna; Latimer, Caitlin S et al. (2018) TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. J Alzheimers Dis 66:1549-1558|
|Bennett, F Chris; Bennett, Mariko L; Yaqoob, Fazeela et al. (2018) A Combination of Ontogeny and CNS Environment Establishes Microglial Identity. Neuron 98:1170-1183.e8|
|Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104|
Showing the most recent 10 out of 117 publications